Schedule a Meeting
Get a SampleAugust 2024
The global artificial intelligence in genomics services market size is calculated at USD 1,086.61 million in 2025 and is forecasted to reach around USD 20,244.03 million by 2034, accelerating at a CAGR of 38.40% from 2025 to 2034. The North America artificial intelligence in genomics services market size surpassed USD 235.54 million in 2024 and is expanding at a CAGR of 38.63% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global artificial intelligence in genomics services market size accounted for USD 785.12 million in 2024 and is predicted to reach around USD 20,244.03 million by 2034, growing at a CAGR of 38.40% from 2025 to 2034. Factors such as increasing demand for precision medicine, rising R&D expenditure, and growing demand for effective handling tools for managing large data are some of the major factors driving the growth of the global artificial intelligence in genomics market in the coming years.
The U.S. artificial intelligence in genomics market size was estimated at USD 164.88 million in 2024 and is predicted to be worth around USD 4,352.97 million by 2034, at a CAGR of 38.73% from 2025 to 2034.
Based on the region, North America dominated the global AI in genomics market in 2023. North America is the home to several leading pharmaceutical and biotechnology companies that has significantly contributed to the growth of the AI in genomics market. The huge investments in the adoption of AI technology in the pharma sector of North America has led to the huge market growth. Further, the presence of huge patient population owing to the presence of high geriatric population and increased prevalence of chronic diseases has resulted in the huge adoption of the AI-based technology in the healthcare sector. It is estimated that more than half of the US population is suffering from one or more chronic diseases. Moreover, by 2060, about 24% of the US population would be of age 65 years or above. Thus the rising demand for innovative medicines and quick treatment services is expected to boost the growth of the North America AI in genomics market.
Asia Pacific is expected to be the fastest-growing market during the forecast period. The surging uses of AI across various application such as agriculture, animal research, diagnostics, and drug discovery is driving the market growth significantly. Moreover, the presence of several top research organizations in the region and rising demand for the AI technology among them is fostering the growth of the AI in genomics market in Asia Pacific region.
Genomics is the popular branch of molecular biology that involves the study of the entire genetic makeup of living beings. The Artificial Intelligence (AI) integration is significantly revolutionizing the healthcare. Artificial Intelligence (AI) offers endless potential applications in the field of genomics. AI algorithms and sophisticated software solutions assist in automating several manual tasks involved in genomic research and reducing the need for human labor which makes the process more cost-effective. By effectively analyzing individual genomic profiles, Artificial Intelligence (AI) algorithms assist in identifying disease risk, recommending targeted therapies, and improving patient outcomes.
Rising demand for clinical diagnostics: Over the years, a significant rise in clinical diagnostic workflows has been increasingly integrated with AI-powered processes to help in disease diagnosis, prognosis, and treatment selection. AI algorithms assist clinicians in making more informed decisions and improving patient outcomes.
Rapid advancements in AI technology: With the rapid advancements in AI technology, AI-powered software solutions are increasingly being developed that are designed for the genomics industry. These solutions are more becoming sophisticated, allowing researchers to analyze and manage genomic data more effectively.
Increase in new product launches: The major market players operating in the AI in genomics market are increasingly focusing on introducing new products to meet the evolving demand for advanced genomic analysis tools. The introduction of new products is expected to enhance the capabilities of researchers and clinicians in leveraging AI for genomics research, diagnosis, and treatment.
Increasing need for big data management : The growing demand for effective handling tools of large data is expected to propel the growth of artificial intelligence in the genomics market in the coming years. Artificial Intelligence (AI) technologies are capable of handling huge datasets with ease, which allows researchers to achieve the results with greater efficiency and accuracy.
| Report Coverage | Details |
| Market Size in 2024 | USD 785.12 Million |
| Market Size by 2034 | USD 20,244.03 Million |
| Growth Rate from 2025 to 2034 | CAGR of 38.40% |
| Largest Market | North America |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | By Offering, By Application, By End User, By Technology, By Functionality, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Rising preference for precision medicine
The increasing preference for precision medicine is expected to boost the growth of the artificial intelligence in genomics market. Precision medicine is increasingly becoming popular as it considers an individual's unique genetic makeup, lifestyle, and other external conditions to create personalized treatment plans for a particular chronic disease. With the rapid advances in algorithms, data sharing, and AI capabilities, the technology has become a crucial tool for unleashing genomic insights. Artificial Intelligence can process large genomic data to identify patterns and correlate them which led to an assisting in initiating personalized treatments. Moreover, AI integration in precision medicine applications in healthcare and treatment concerns, mainly cancer. AI assists in analyzing genomic data, the genetic makeup of a mutation in cancer, and developing the best therapies beneficial for the patient's recovery. Thereby, driving the market's growth.
Lack of skilled workforce
The lack of skilled workforce is anticipated to hamper the market’s growth during the forecast period. Skilled expertise is required in both AI and genomics. To extract and label unstructured data demands a proficient workforce in addition to patient information is very sensitive and also subject to strict privacy regulations. Such factor in restricting the expansion of the market in the coming years.
Increasing Investments by Industry Players
The rising investment by prominent market players is projected to offer lucrative growth opportunities to the market during the analysis period. Artificial Intelligence (AI) has nearly endless potential applications in the field of genomics in revolutionizing healthcare. The rising investments in the fields of AI and genomics, as organizations, governments, research institutes, and private companies are increasingly focusing on developing effective treatments for chronic diseases, particularly cancer. Therefore, these investment assists in promoting and facilitating the adoption of AI tools and technologies in the genomics industry to benefit patients, clinicians, and the overall healthcare system.
Based on the offering, the software segment dominated the global AI in genomics market in 2023. This growth is attributed to the increased adoption of the AI-based software in the research and development phase of the drug discovery and drug development activities. Moreover, the presence of several number of leading pharmaceutical companies along with the numerous contract research organization and the higher adoption of software for collecting, storing, and analyzing data has led to the growth of the software segment in the global AI in genomics market. The rising number of contract research organizations, biotech companies, and healthcare providers coupled with the rising adoption of the AI technology is expected to have a significant and positive impact on the growth of the software segment in the forthcoming years.
On the other hand, the services is expected to be the fastest-growing segment during the forecast period. The lack of availability of the AI skilled workers is a major factor behind the rising demand for the services in the market. The operation of AI-based systems needs special skills and understanding of this latest technology and hence the demand for services is expected to grow significantly during the forecast period.
The machine learning segment held the largest share of artificial intelligence in genomics market in 2024, the segment is expected to sustain the position throughout the forecast period. Machine learning has become a crucial tool in genomics research. Machine learning assists scientists or researchers to make relevant discoveries and improve the comprehension of the genetic basis in chronic diseases. The algorithms of machine learning assist in automating tasks that would be time-consuming with manual efforts including the identification of potential drug targets.
On the other hand, the computer vision segment is expected to grow significantly during the forecast period. The segment’s growth is majorly driven by the advancement of genomics research. Computer vision involves the use of algorithms to effectively analyze data and interpret images are increasingly being applied to genomics. Moreover, it also assists in automating tasks and offering more accurate results. Such factors are driving the growth of the segment in the coming years.
The drug discovery & development segment dominated the global AI in genomics market in 2024. The rising prevalence of various chronic, infectious, and gene related diseases among the global population is significantly attracting investments towards the drug discovery & development activities. The rising need to control costs and enhance efficiency and provide desired results, the adoption of the AI in genomics significantly fostered in the past decade. Drug discovery and development became the highest adopter of the AI technology in the genomics industry. Moreover, the growing government and corporate efforts to decrease the healthcare costs has resulted in the adoption of the AI in the drug discovery and development activity.
The precision medicine is expected to be the most opportunistic segment during the forecast period. The rising advances in the oncology and cancer biologics is driving the growth of the precision medicine segment. The rising adoption of AI in the precision medicine in the prevention and management of cancer is expected to significantly drive the growth of the precision medicine segment in the global AI in genomics market.
The genome sequencing segment accounted for the highest revenue share in 2024 and is anticipated to grow at a robust CAGR over the forecast period. The segment’s growth is majorly attributed to the rising use of AI in genomics to accelerate the process of sequencing genomes to find genetic patterns. AI integration in genomic data analysis to personalize medicines based on individual's genetics. AI minimizes the time and expense associated with genome sequencing. AI reduces errors and improves the accuracy of genome sequencing. AI rapidly and correctly pinpoints genetic variations related to any diseases or traits. Thus driving the growth of the segment during the forecast period. In addition, the companies involved in genome sequencing collaborate with Artificial Intelligence to accelerate the procedures. For instance, in May 2024, Bangalore-based informatics startup G-KnowMe entered into a partnership with researchers at the University of Cambridge and the Cambridge University Hospitals NHS Foundation Trust (CUH) to develop an automated workflow for interpreting data from sequencing the entire genome of cancers. As genome sequencing costs drastically fall, the line between its usage in clinical research and clinical management of the disease is blurred. The lure to extract maximum patient-relevant information is increasing, for better management of the disease. This partnership aims to automate clinical interpretation of data from sequencing the entire genome of cancers.
The gene editing segment is expected to grow at the fastest rate during the forecast period of 2024 to 2034. AI-driven genomic analysis is widely used in identifying genetic variations associated with diseases or patients' responses to any specific treatment for rare and chronic diseases. Artificial Intelligence (AI) plays an important role in guiding the genome editing process by assisting in the selection of optimal editing strategies. Artificial Intelligence (AI) algorithms significantly contribute to the identification of well-suited delivery strategies for the genome editor. Thereby, bolstering the market’s expansion in the coming years.
Based on the end user, the pharmaceutical and biotech companies segment dominated the global AI in genomics market in 2023. The presence of the leading pharmaceutical companies across the globe is significantly driving the demand for the AI technology for various activities like making precision medicine, drug discovery, drug development, and manufacturing of diagnostic devices using AI technology. Further, the rapidly growing biotechnology companies across the globe is significantly responsible for the growth of the AI in genomics market owing to its rising adoption of the AI technology.
Healthcare providers is expected to be the fastest-growing segment during the forecast period. The growing geriatric population and rising prevalence of diseases is significantly boosting the number of hospital admissions. The healthcare providers are under immense pressure to provide quick and enhanced services to the patients at low cost. Therefore, the healthcare sector is significantly investing in the adoption of the AI-based services and software to reduce healthcare costs, improve care quality, and provide quick treatment services to the patients.
In November 2024, Dante Genomics announced the integration of Generative AI capabilities into its first product, the Dante Labs Whole Genome Platform. This milestone represents a significant step in the company’s mission to make genomic data more usable and accessible to researchers and individuals.
By Offering
By Application
By End User
By Technology
By Functionality
By Geography
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
August 2024
December 2024
September 2024
April 2025